|
Volume 25, Issue 2 (March 2023) 25, 192–197; 10.4103/aja2022105
The role of glutamine metabolism in castration-resistant prostate cancer
Zhao, Bing1; Wang, Jing2; Chen, Li1; Wang, Hong3; Liang, Chao-Zhao4,5,6; Huang, Jiaoti7,8,; Xu, Ling-Fan4,5,6
1Department of Geriatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230002, China
2Department of Urologic Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031, China
3Department of Nursing, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, China
4Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, China
5Institute of Urology, Anhui Medical University, Hefei 230001, China
6Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230001, China
7Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA
8Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27710, USA
Correspondence: Dr. J Huang (Jiaoti.huang@duke.edu) Dr. LF Xu (ayfyxlf@163.com)
Received: 20 August 2022; Accepted: 17 November 2022; published online: 10 January 2023
| Abstract |
|
Reprogramming of metabolism is a hallmark of tumors, which has been explored for therapeutic purposes. Prostate cancer (PCa), particularly advanced and therapy-resistant PCa, displays unique metabolic properties. Targeting metabolic vulnerabilities in PCa may benefit patients who have exhausted currently available treatment options and improve clinical outcomes. Among the many nutrients, glutamine has been shown to play a central role in the metabolic reprogramming of advanced PCa. In addition to amino acid metabolism, glutamine is also widely involved in the synthesis of other macromolecules and biomasses. Targeting glutamine metabolic network by maximally inhibiting glutamine utilization in tumor cells may significantly add to treatment options for many patients. This review summarizes the metabolic landscape of PCa, with a particular focus on recent studies of how glutamine metabolism alterations affect therapeutic resistance and disease progression of PCa, and suggests novel therapeutic strategies.
Keywords: castration resistance; glutamine metabolism; prostate cancer; tumor metabolism
Full Text |
PDF |
|
| |
| Browse: 263 |
|
